Controversial U.S. Vaccine Policy Change Sparks Outcry

The U.S. ACIP's vote to remove broad recommendations for newborn hepatitis B vaccinations has sparked controversy. Experts warn the change could increase infant infection rates, clashing with longstanding public health policies. Critics, including medical professionals, argue the decision is not data-driven and risks children's health.

The U.S. Advisory Committee on Immunization Practices voted to remove the recommendation of hepatitis B vaccines for all newborns, igniting a firestorm of criticism from health officials and experts. This decision, part of a sweeping change under Health Secretary Robert F. Kennedy Jr., challenges established public health protocols.

Senate HELP Committee Chairman Bill Cassidy, a liver specialist, stressed the potential rise in hepatitis B cases, urging the Acting CDC Director to retain current guidelines. Meanwhile, Dorit Reiss, a vaccine law expert, highlighted the absence of expertise and data to support the decision, expressing concerns for infant safety.

Medical professionals, including Dr. Cody Meissner and Dr. William Schaffner, criticized the committee for endangering children's health. They advocated for continued standard vaccination practices at birth, despite the committee's contentious policy shift.